he EARLY ACS trial, presented at the American College of Cardiology 2009 Scientific Sessions, addressed the long-debated question of whether it was better to give GP IIb/IIIa blockers upstream to all high-risk ACS patients or to use them selectively in the cath lab.

Join Drs Harlan Krumholz, Sanjay Kaul, and Robert Harrington as they review the results of the trial and go into detail about the contentious and sometimes confusing issues surrounding the use of GP IIb/IIIa inhibitors.